DPP-4 inhibitors used to treat type 2 diabetes, this class includes different brands in single molecule or combined with other molecules like metformin.
DPP-4 inhibitors brands:
| Brand name | Active ingredient(s) |
|---|---|
| Januvia | sitagliptin |
| Janumet | sitagliptin and metformin |
| Janumet XR | sitagliptin and metformin extended release |
| Onglyza | saxagliptin |
| Kombiglyze XR | saxagliptin and metformin extended release |
| Tradjenta | linagliptin |
| Glyxambi | linagliptin and empagliflozin |
| Jentadueto | linagliptin and metformin |
| Nesina | alogliptin |
| Kazano | alogliptin and metformin |
| Oseni | alogliptin and pioglitazone |
According to FDA, 33 cases of severe arthralgia have been reported with the use of dipeptidyl peptidase-4 (DPP-4) inhibitors from October 16, 2006, approval date of the first DPP-4 inhibitor, through December 31, 2013.
Sitagliptin was the most frequently reported with 28 cases , followed by saxagliptin 5 cases , linagliptin 2 cases , alogliptin only 1 case and vildagliptin two cases.
Although the number of reported cases is very low compared to the patients who use DPP-4 inhibitors, you should report any severe joint pain or any other related symptoms to your health care professional.
To download the full FDA safety warning please follow this link :
http://www.fda.gov/downloads/Drugs/DrugSafety/UCM460038.pdf